Lumasiran

DRUG8 trials

Conditions

AGTCardiovascular DiseaseCardiovascular Risk FactorChronic Kidney Disease Requiring Chronic DialysisElevated Urinary Oxalate LevelsHaemodialysisHyperoxalemiaPH1

Phase 1

Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1

CompletedNCT02706886

Alnylam PharmaceuticalsPrimary Hyperoxaluria Type 1 (PH1)

Start: 2016-03-08End: 2019-01-23Updated: 2020-01-30

Phase 2

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

CompletedNCT03350451

Alnylam PharmaceuticalsAGT, PH1, Primary Hyperoxaluria +2

Start: 2018-04-04End: 2023-02-07Updated: 2024-04-25

A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

TerminatedNCT05161936

Alnylam PharmaceuticalsElevated Urinary Oxalate Levels, Recurrent Calcium Oxalate Kidney Stone Disease

Start: 2022-01-27End: 2022-11-01Updated: 2024-05-22

Lumasiran in Hyperoxalaemic Patients on Haemodialysis

RecruitingNCT06225544

Charite University, Berlin, GermanyCardiovascular Disease, Cardiovascular Risk Factor, Chronic Kidney Disease Requiring Chronic Dialysis +2

Start: 2024-04-14End: 2025-03-01Target: 50Updated: 2024-08-21

Phase 3

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

CompletedNCT03681184

Alnylam PharmaceuticalsPrimary Hyperoxaluria Type 1 (PH1)

Start: 2018-11-27End: 2024-01-12Updated: 2024-08-12

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

CompletedNCT03905694

Alnylam PharmaceuticalsPrimary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1)

Start: 2019-04-22End: 2024-07-26Updated: 2025-02-14

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

CompletedNCT04152200

Alnylam PharmaceuticalsPrimary Hyperoxaluria, Primary Hyperoxaluria Type 1

Start: 2020-01-21End: 2025-06-23Updated: 2025-07-18

Unknown Phase

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

NCT04125472

Alnylam PharmaceuticalsPrimary Hyperoxaluria

Updated: 2024-02-16

2025-12-12

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1

Clinical Journal of the American Society of Nephrology2025-12-04

#2388 Long-term efficacy and safety in the 60-month, Phase 3 ILLUMINATE-B trial of lumasiran in infants and young children with primary hyperoxaluria type 1

Nephrology Dialysis Transplantation2025-10-01

Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria

Nephrology Dialysis Transplantation2025-09-191 citations

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial

Frontiers in Pediatrics2024-09-166 citations

#190 Long-term treatment with lumasiran: final results from the phase 2 open-label extension study

Nephrology Dialysis Transplantation2024-05-01

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.

2024-04-267 citations

NS-AUA 2023 Annual Meeting Abstracts – Endourology, Stones

Canadian Urological Association Journal2023-10-03

MP10-01 EFFICACY AND SAFETY OF LUMASIRAN IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1: 36-MONTH ANALYSIS OF THE ILLUMINATE-A TRIAL

The Journal of Urology2023-03-23

Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1

Kidney International2023-03-0412 citations

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial

Pediatric Nephrology2022-08-0142 citations

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.

2022-07-1456 citations

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1

Clinical Journal of the American Society of Nephrology2021-05-1377 citations

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

New England Journal of Medicine2021-03-31465 citations